As of May, 14 Amphastar Pharmaceuticals, Inc. (AMPH) Analysts See $0.12 EPS

April 17, 2018 - By Eula Gilbert

Big Money Sentiment increased to 1.15 in 2017 Q4. It has change of 0.24, from 2017Q3’s 0.91. The ratio increased due to Amphastar Pharmaceuticals, Inc. positioning: 5 sold and 36 reduced. 16 funds amassed positions and 31 increased positions. Investors holded 20.04 million in 2017Q3 but now own 20.28 million shares or 1.20% more.
Citigroup stated it has 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Rothschild Asset Management invested 0.07% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Pnc Fincl Service Grp stated it has 1,422 shs or 0% of all its holdings. Dimensional Fund Advsrs L P has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Metropolitan Life invested in 0% or 11,917 shs. Nordea Investment Mngmt, a Sweden-based fund reported 130,077 shs. Winslow Evans & Crocker owns 1,758 shs. Moreover, Kbc Grp Incorporated Nv has 0.01% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Legal And General Grp Public Limited Co accumulated 65,586 shs or 0% of the stock. Cubist Systematic Strategies Limited Liability Company accumulated 1,123 shs or 0% of the stock. Assetmark Inc has 11 shs for 0% of their capital. Ubs Asset Mgmt Americas owns 401,537 shs. Qs Investors Llc stated it has 79,064 shs or 0.01% of all its holdings. Comerica Bancorporation holds 0% or 36,536 shs in its capital. Northern Tru Corp holds 469,432 shs or 0% of its capital.

Earnings report for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is awaited On May, 14., Zacks reports. Last year’s earnings per share was $0.03, while now analysts expect change of 300.00 % up from current $0.12 earnings per share. AMPH’s profit could hit $5.56 million with 39.79 P/E in case $0.12 earnings per share is announced. Wall Street predicts 20.00 % EPS growth as of May, 14. On during the last trading session the stock decreased $0.08 or 0.42%, reaching $19.1.Amphastar Pharmaceuticals, Inc. has volume of 1,828 shares. Since April 17, 2017 AMPH has risen 29.43% and is uptrending. AMPH outperformed the S&P500 by 17.88%.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Coverage

Total analysts of 5 have positions in Amphastar Pharmaceuticals (NASDAQ:AMPH) as follows: 3 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 60%. Since October 20, 2017 according to StockzIntelligence Inc Amphastar Pharmaceuticals has 10 analyst reports. On Thursday, November 9 Raymond James downgraded the shares of AMPH in report to “Hold” rating. On Friday, October 20 the firm earned “Buy” rating by Piper Jaffray. On Tuesday, January 30 the rating was maintained by Piper Jaffray with “Buy”. The company rating was maintained by BMO Capital Markets on Thursday, October 26. On Tuesday, March 13 the firm has “Buy” rating by Needham given. On Friday, December 1 Needham maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) with “Buy” rating. In Thursday, November 9 report Jefferies maintained it with “Buy” rating and $23.0 target. On Friday, November 10 BMO Capital Markets maintained the shares of AMPH in report with “Market Perform” rating. The stock rating was maintained by Jefferies with “Buy” on Friday, October 27. On Tuesday, March 13 the firm has “Market Perform” rating given by BMO Capital Markets.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products.The firm is valued at $885.30 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.212.22 is the P/E ratio. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: